Genotype 1b and severity of posttransplant recurrence of hepatitis C infection— unconvictable felon or wrongly accused?
✍ Scribed by Michael Charlton
- Book ID
- 102468139
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 57 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1527-6465
No coin nor oath required. For personal study only.
✦ Synopsis
Background & Aims: Liver transplantation for hepatitis C virus (HCV)-related liver disease is characterized by frequent graft infection by HCV. The prognosis and risk factors for morbidity and mortality in this condition were determined. Methods: A retrospective study of 652 consecutive anti-HCV-positive patients undergoing liver transplantation between 1984 and 1995 in 15 European centers was conducted; 102 patients coinfected with hepatitis B virus (HBV) received immunoglobulin prophylaxis for antibody to hepatitis B surface antigen. Results: Overall, 5-year survival was 72%. Five-year actuarial rates of hepatitis and cirrhosis were 80% and 10%. Genotypes 1b, 1a, and 2 were detected in 214 (80%), 24 (9%), and 24 (9%) of 268 patients analyzed. The only discriminant factor for patient or graft survival was hepatocellular carcinoma as primary indication. Independent risk factors for recurrent hepatitis included the absence of HBV coinfection before transplantation (relative risk [RR], 1.7; 95% confidence interval [CI], 1.2-2.6; P ؍ 0.005), genotype 1b (RR, 2; 95% CI, 1.3-2.9; P ؍ 0.01), and age G49 years (RR, 1.4; 95% CI, 1.1-1.8; P ؍ 0.01). Conclusions: The results of transplantation for HCV-related disease are compromised by a significant risk of cirrhosis, although 5-year survival is satisfactory. Genotype 1b, age, and absence of pretransplantation coinfection by HBV are risk factors for recurrent HCV.
📜 SIMILAR VOLUMES
Interferon lambda 1 (IFN-k1) is a type III IFN that produces intracellular responses similar to those of IFN-a but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an improved safety profile. This was an open-label three-part study